WASHINGTON (AP) — Warning of tough days ahead with surging COVID-19 infections, the director of the National Institutes of Health said Sunday the U.S. could decide in the next couple weeks whether to offer coronavirus booster shots to more Americans this fall.
Dr. Francis Collins also pleaded anew for unvaccinated Americans to get their shots, calling them “sitting ducks” for a delta variant that is ravaging the country and showing little sign of letting up.
“This is going very steeply upward with no signs of having peaked out,” he said.
Federal health officials have been actively looking at whether extra shots for the vaccinated may be needed as early as this fall, reviewing case numbers in the U.S. “almost daily” as well as the situation in other countries such as Israel, where preliminary studies suggest the vaccine’s protection against serious illness dropped among those vaccinated in January.
Israel has been offering a coronavirus booster to people over 60 who have already been vaccinated.
No U.S. decision has been made because cases here so far still indicate that people remain highly protected from COVID-19, including the delta variant, after receiving the two-dose Pfizer or Moderna regimen or the one-shot Johnson & Johnson vaccine.
But U.S. health officials made clear Sunday they are preparing for the possibility that the time for boosters may come sooner than later.
“There is a concern that the vaccine may start to wane in its effectiveness,” Collins said. “And delta is a nasty one for us to try to deal with. The combination of those two means we may need boosters, maybe beginning first with health care providers, as well as people in nursing homes, and then gradually moving forward” with others, such as older Americans.
He said because the delta variant only started hitting the U.S. hard in July, the “next couple of weeks” of case data will help the U.S. make a decision.
Moderna President Stephen Hoge said seeing some “breakthrough” infections emerge among the vaccinated within six months has been surprising, even if most symptoms so far have not been life-threatening. “I think that suggests we are going to need booster vaccines to get through the winter,” he said.
Last week, the Food and Drug Administration said p eople with weakened immune systems can get an extra dose of the Pfizer or Moderna vaccines to better protect them as the delta variant continues to surge.
“If it turns out as the data come in, we see we do need to give an additional dose to people in nursing homes, actually, or people who are elderly, we will be absolutely prepared to do that very quickly,” said Dr. Anthony Fauci, who is President Joe Biden’s chief medical adviser.
While the U.S. currently is seeing an average of about 129,000 new infections a day — a 700% increase from the beginning of July — that number could jump in the next couple weeks to 200,000, a level not seen since among the pandemic’s worst days in January and February, Collins said.
Both he and Fauci stressed that the best way to stem the virus is for the unvaccinated to get their shots.
Currently, about 60% of the U.S. population has gotten at least one dose and nearly 51% are fully vaccinated, according to the Centers for Disease Control and Preventio n. Areas with low vaccination rates have been particularly hit hard with infections, such as Louisiana, Texas, Florida and Mississippi.
“That’s heartbreaking considering we never thought we would be back in that space again,” Collins said of surging infections. “But here we are with the delta variant, which is so contagious, and this heartbreaking situation where 90 million people are still unvaccinated who are sitting ducks for this virus, and that’s the mess we’re in. We’re in a world of hurt.”
Fauci said as more people get their shots, in many places everyone — both the vaccinated and unvaccinated — will have to do their part with “mitigation,” such as mask-wearing in schools and other public spaces.
“We’ve just got to realize that we’re dealing with a public health crisis,” he said. “The more you get infections, the more spread you get, the greater opportunity the virus has to continue to evolve and mutate.”
Collins spoke on “Fox News Sunday,” Fauci appeared on CBS’ “Face the Nation” and Hoge was on Fox News Channel’s “Sunday Morning Futures.”
Hope Yen, The Associated Press
FDA panel rejects plan to offer Pfizer booster shots against COVID-19 to most Americans – WAGM
WASHINGTON (AP) — Dealing the White House a stinging setback, a government advisory panel overwhelmingly rejected a plan Friday to give Pfizer COVID-19 booster shots across the board, and instead endorsed the extra vaccine dose only for those who are 65 or older or run a high risk of severe disease.
The twin votes represented a heavy blow to the Biden administration’s sweeping effort, announced a month ago, to shore up nearly all Americans’ protection amid the spread of the highly contagious delta variant.
The nonbinding recommendation — from an influential committee of outside experts who advise the Food and Drug Administration — is not the last word. The FDA will consider the group’s advice and make its own decision, probably within days. And the Centers for Disease Control and Prevention is set to weigh in next week.
In a surprising turn, the advisory panel rejected, 16-2, boosters for almost everyone. Members cited a lack of safety data on extra doses and also raised doubts about the value of mass boosters, rather than ones targeted to specific groups.
Then, in an 18-0 vote, it endorsed extra shots for people 65 and older and those at risk of serious disease. Panel members also agreed that health workers and others who run a high risk of being exposed to the virus on the job should get boosters, too.
That would help salvage part of the White House’s campaign but would still be a huge step back from the far-reaching proposal to offer third shots of both the Pfizer and Moderna vaccines to Americans eight months after they get their second dose.
The White House sought to frame the action as progress.
“Today was an important step forward in providing better protection to Americans from COVID-19,” said White House spokesman Kevin Munoz. “We stand ready to provide booster shots to eligible Americans once the process concludes at the end of next week.”
The CDC has said it is considering boosters for older people, nursing home residents and front-line health care workers, rather than all adults.
The FDA and CDC will most likely decide at some later point whether people who received the Moderna or Johnson & Johnson shots should get boosters.
During several hours of vigorous debate Friday, members of the panel questioned the value of offering boosters to almost everybody 16 and over.
“I don’t think a booster dose is going to significantly contribute to controlling the pandemic,” said Dr. Cody Meissner of Tufts University. “And I think it’s important that the main message we transmit is that we’ve got to get everyone two doses.”
Dr. Amanda Cohn of the CDC said, “At this moment it is clear that the unvaccinated are driving transmission in the United States.”
In a statement, Kathrin U. Jansen, Pfizer head of vaccine research and development, said the company continues to believe that boosters will be a “critical tool in the ongoing effort to control the spread of this virus.”
Scientists inside and outside the government have been divided recently over the need for boosters and who should get them, and the World Health Organization has strongly objected to rich nations giving a third round of shots when poor countries don’t have enough vaccine for their first.
While research suggests immunity levels in those who have been vaccinated wane over time and boosters can reverse that, the Pfizer vaccine is still highly protective against severe illness and death, even amid the delta variant.
The unexpected turn of events could reinforce criticism that the Biden administration got out ahead of the science in its push for boosters. President Joe Biden promised early on that his administration would “follow the science,” in the wake of disclosures of political meddling in the Trump administration’s coronavirus response.
The FDA panel’s overwhelming initial rejection came despite full-throated arguments about the need for boosters from both Pfizer and health officials from Israel, which began offering boosters to its citizens in July.
Sharon Alroy-Preis of Israel’s Ministry of Health said the booster dose improves protection tenfold against infection in people 60 and older.
“It’s like a fresh vaccine,” bringing protection back to original levels and helping Israel “dampen severe cases in the fourth wave,” she said.
Representatives for Pfizer argued that it is important to start shoring up immunity before protection begins to erode. A company study of 44,000 people showed effectiveness against symptomatic COVID-19 was 96% two months after the second dose, but had dropped to 84% by around six months.
Both Pfizer and the Israeli representatives faced pushback from panelists. Several were skeptical about the relevance of Israel’s experience to the U.S. Another concern was whether third doses would exacerbate serious side effects, including rare instances of heart inflammation in younger men.
Pfizer pointed to Israeli data from nearly 3 million boosters to suggest side effect rates would be similar to those already reported.
Dr. Paul Offit, a vaccine expert at Children’s Hospital of Philadelphia, said he was supportive of a third dose for adults over 60 or 65, but “I really have trouble” supporting it for anyone down to age 16.
While an extra shot would probably at least temporarily reduce cases with mild or no symptoms, “the question becomes what will be the impact of that on the arc of the pandemic, which may not be all that much,” Offit said.
Biden’s top health advisers, including the heads of the FDA and CDC, first announced plans for widespread booster shots in mid-August, setting the week of Sept. 20 as an all-but-certain start date. But that was before FDA staff scientists had completed their own assessments of the data.
Earlier this week, two top FDA vaccine reviewers joined a group of international scientists in publishing an editorial rejecting the need for boosters in healthy people. The scientists said studies show the shots are working well.
On Friday, U.S. Surgeon General Dr. Vivek Murthy said the Biden administration announcement was not aimed at pressuring regulators to act but was instead an attempt to be transparent with the public and be prepared in the event that boosters won approval.
“We have always said that this initial plan would be contingent on the FDA and the CDC’s independent evaluation,” Murthy said.
The Biden plan has also raised major ethical concerns about impoverished parts of the world still clamoring for vaccine. But the administration argued that the plan was not an us-or-them choice, noting that the U.S. is supplying large quantities of vaccine to the rest of the globe.
The U.S. has already approved Pfizer and Moderna boosters for certain people with weakened immune systems, such as cancer patients and transplant recipients.
Some Americans, healthy or not, have managed to get boosters, in some cases simply by showing up and asking for a shot. And some health systems already are offering extra doses to high-risk people.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
Copyright 2021 The Associated Press. All rights reserved.
'You'll see': Quebec health minister promises bold proposals to solve critical nurse shortage – CTV News Montreal
QUEBEC CITY —
Quebec Health Minister Christian Dube is promising a plan with bold and original ideas to try to attract thousands of nurses back to the public health network and prevent a breakdown of services.
On Friday, during a scrum with journalists in Lévis, Minister Dube reaffirmed his commitment to doing everything possible to offer nurses a more attractive work environment, different from what they’ve known until now, to convince them to return to the public system.
For years, nurses have complained about the widespread practice of demanding mandatory overtime, which regularly forces them to work exhausting double shifts.
The magnitude of the current crisis, with a shortage of over 4,000 nurses keeping the network from functioning normally, is now pushing the Legault government to pay closer attention to their grievances.
Minister Dube promised to announce new incentives next week, both financial and professional, that he believes will bring back nurses who have opted for early retirement in recent years or who have chosen to practice in the private sector.
He intends to be bold in the way he goes about it, he said.
“You’ll see,” said the minister.
“We’re going to make announcements that might have surprised us a few months or a few years ago, but which will be prompted by the fact that we’ve looked at new ways of doing things with the pandemic.”
While he waits for nurses’ reaction to these soon-to-be-announced short-term incentives, Dube is also planning to implement a more long-term, global reorganization, he said, with “much more structural proposals on the table.”
The day before, the minister had pledged to prevent any service disruptions in the health network, despite the significant shortage of personnel.
He’s also contending with the likelihood the problem will worsen as of October 15, the date by which all health-care staff in Quebec will have to be double vaccinated against COVID-19 to stay on the job.
Those who don’t comply will be suspended without pay for an indefinite period. It’s a scenario that suggests the situation will become even more difficult to manage, as there are an estimated 20,000 unvaccinated employees in the network, at least half of whom provide direct patient care.
This report by The Canadian Press was first published in French on Sept. 17, 2021.
COVID-19 booster debate in US heads to FDA vaccine advisory committee – National | Globalnews.ca – Global News
The debate over whether Americans should receive a booster dose of the Pfizer/BioNTech COVID-19 vaccine moves to a panel of independent expert advisers to the U.S. Food and Drug Administration on Friday.
While U.S. health officials, some other countries and vaccine makers have said boosters are needed, many scientists and vaccine experts disagree.
The FDA staff said in documents prepared for the committee this week that the vaccine Pfizer Inc developed with Germany’s BioNTech SE is still very effective at preventing severe illness and death and that the evidence is mixed on whether its efficacy declines over time.
COVID-19: Boris Johnson reverses course on vaccine passports for England, announces UK booster program
Pfizer, which is arguing for broad use of a third shot, submitted data from an analysis of over 300 participants in its late stage clinical trial showing that the vaccine’s efficacy diminished by around 6% every two months after the second dose, and that an additional shot boosted immunity.
The FDA’s Vaccines and Related Biological Products Advisory Committee will also consider data from Israel, which has been administering booster doses of the Pfizer/BioNTech vaccine.
It began offering a COVID-19 booster to people as young as age 12 last month, expanding a campaign that began in July for people over 60.
An analysis by Israeli scientists published on Wednesday in the New England Journal of Medicine found that among 1.1 million people age 60 or older who had been fully vaccinated at least 5 months earlier, those who received a booster were less likely to be infected or become severely ill than those who did not get the third shot.
The Israeli Health Ministry said in documents on Friday that immunity against infection declined during July among all age groups, but particularly among people aged 60 and over who had been vaccinated in January.
Immunity against severe disease dropped in that older group, and such a decline may occur in younger groups aged 50 to 59 as well as 40 to 49, it said. The ministry also said the booster dose did not raise new safety issues.
The booster debate gained urgency as U.S. COVID-19 hospitalizations and deaths surged due to the highly transmissible Delta variant of the virus, mostly among the unvaccinated. But infections among fully vaccinated people have risen and they can spread the virus on occasion, mostly to unvaccinated people.
‘LARGER POPULATIONS MAY TAKE LONGER’
Wall Street analysts see the additional shots ultimately getting approved for a broad population.
“We expect a potential positive FDA support for boosters for elderly ahead of Biden’s rollout, but larger populations may take longer for broad support and approval,” Jefferies analyst Michael Yee said in an email.
Scientists say the strongest evidence for boosters is for older adults and other high risk populations.
“My guess is we are going to end up with a recommendation for booster doses for a certain subpopulation, such as adults older than 65,” said Bill Moss, executive director of the International Vaccine Access Center at the Johns Hopkins Bloomberg School of Public Health.
Immunocompromised offered vaccine booster shot. Who is eligible?
More than 1.9 million Americans have already gotten a booster dose after the government authorized them for people with compromised immune systems, according to the U.S. Centers for Disease Control and Prevention (CDC).
The panel will vote on if safety and effectiveness data support approval of a booster at least 6 months after the second dose for people aged 16 and older. The vote is scheduled for between 2:25 pm ET and 4:45 pm ET.
Eight top health officials in the Biden Administration – including the heads of the FDA and the CDC – said in August they believe booster shots will be needed because emerging data shows that protection against COVID-19 decreases over time.
The U.S. is planning a booster campaign for the week of Sept. 20, contingent on backing by the FDA and CDC.
Moderna Inc has also asked for approval of a booster and released data on Wednesday showing that protection from its vaccine also wanes over time. That is not expected to be discussed at Friday’s meeting.
(Reporting by Manojna Maddipatla and Ankur Banerjee in Bengaluru; Editing by Caroline Humer and Bill Berkrot)
© 2021 Reuters
Blue Jays need to determine next steps for Ryu after thumping from Twins – Sportsnet.ca
Some Apple Card owners hit snags with iPhone 13 preorders – CNET
Chinese astronauts return with first mission for space station construction accomplished – CCTV
Silver investment demand jumped 12% in 2019
Europe kicks off vaccination programs | All media content | DW | 27.12.2020 – Deutsche Welle
Iran anticipates renewed protests amid social media shutdown
Health19 hours ago
Prepping Your Home for the Canadian Winter
Health15 hours ago
'Absolutely gut-wrenching:' Waterloo Region child under the age of 10 dies after contracting COVID-19 – CP24 Toronto's Breaking News
Health16 hours ago
88 new COVID-19 cases in Manitoba Friday; more than half not vaccinated – CTV News Winnipeg
Politics24 hours ago
Pandemic politics fuel long-shot Republican challenges to Texas Gov. Greg Abbott – NBC News
News24 hours ago
B.C. says it can't take patients from Alberta's overwhelmed ICUs – CBC.ca
Sports24 hours ago
Ticats list Watford as starting QB vs. Stampeders – TSN
Art19 hours ago
Jidar, Rabat's street art festival draws international attention | | AW – The Arab Weekly
Sports13 hours ago
Blue Jays right-hander Berrios won’t miss any time after abdominal scare – Sportsnet.ca